NCT Number: NCT00045903
Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder
This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.
Looking for future studies?
Notify MeKey information
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
New York State Psychiactic Institute, Anxiety Disorders Clinic, New York, United States
About this study
Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication.
For information on a related study, please follow this link:
http://clinicaltrials.gov/show/NCT00389493
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Obsessive-Compulsive Disorder (OCD) diagnosis
- Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD
Exclusion criteria
- Medical or psychiatric conditions that would make participation in the study hazardous
- Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD
Treatment and study plan
Stress Management Therapy (Cognitive Behavior Therapy)
BehavioralPrimary outcomes
-
Obsessive-compulsive symptoms measured at Month 2
Time frame: 2 months
Secondary outcomes
-
General functioning measured at Month 2
Time frame: 2 months
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
New York State Psychiatric Institute
Other
Collaborators
- National Institute of Mental Health (NIMH)
Registry information
Official study title
CBT Augmentation for SRI Pharmacotherapy in OCD
Acronym: Aug1
Important dates
- Study start
- 2000
- Primary completion
- 2007
- Study completion
- 2007
- First posted
- Sep 17, 2002
- Registry last updated
- Apr 23, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
NCT06299319
Anxiety Disorders, Mental Disorders
Toronto, Ontario, Canada
View Trial DetailsA Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
NCT05624528
Anxiety Disorders, Mental Disorders
Chicago, Illinois, United States
View Trial DetailstDCS for Treatment Resistant Obsessive Compulsive Disorder
NCT03304600
Anxiety Disorders, Mental Disorders
Lyon, France
View Trial DetailsTranscranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
NCT05521074
Anxiety Disorders, Mental Disorders
Boston, Massachusetts, United States
View Trial Details